298 related articles for article (PubMed ID: 15630049)
61. Endothelin-A receptor antagonism attenuates the hypertension and renal injury in Dahl salt-sensitive rats.
Kassab S; Miller MT; Novak J; Reckelhoff J; Clower B; Granger JP
Hypertension; 1998 Jan; 31(1 Pt 2):397-402. PubMed ID: 9453335
[TBL] [Abstract][Full Text] [Related]
62. CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats.
Arai K; Tsuruoka H; Homma T
Eur J Pharmacol; 2015 Dec; 769():266-73. PubMed ID: 26607463
[TBL] [Abstract][Full Text] [Related]
63. P2X(7) receptor antagonism attenuates the hypertension and renal injury in Dahl salt-sensitive rats.
Ji X; Naito Y; Hirokawa G; Weng H; Hiura Y; Takahashi R; Iwai N
Hypertens Res; 2012 Feb; 35(2):173-9. PubMed ID: 21918525
[TBL] [Abstract][Full Text] [Related]
64. Enhancement of intrarenal angiotensinogen in Dahl salt-sensitive rats on high salt diet.
Kobori H; Nishiyama A; Abe Y; Navar LG
Hypertension; 2003 Mar; 41(3):592-7. PubMed ID: 12623964
[TBL] [Abstract][Full Text] [Related]
65. Interactions of hypercholesterolemia and hypertension in initiation of glomerular injury.
Tolins JP; Stone BG; Raij L
Kidney Int; 1992 May; 41(5):1254-61. PubMed ID: 1614039
[TBL] [Abstract][Full Text] [Related]
66. Do COX-2 inhibitors reduce renal fibrosis?
Harding P
J Hypertens; 2004 Jan; 22(1):43-5. PubMed ID: 15106792
[No Abstract] [Full Text] [Related]
67. Handling 22NaCl by the blood-brain barrier and kidney: its relevance to salt-induced hypertension in dahl rats.
Simchon S; Manger W; Golanov E; Kamen J; Sommer G; Marshall CH
Hypertension; 1999 Jan; 33(1 Pt 2):517-23. PubMed ID: 9931158
[TBL] [Abstract][Full Text] [Related]
68. Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects.
Schwartz JI; Dallob AL; Larson PJ; Laterza OF; Miller J; Royalty J; Snyder KM; Chappell DL; Hilliard DA; Flynn ME; Cavanaugh PF; Wagner JA
J Clin Pharmacol; 2008 Jun; 48(6):745-54. PubMed ID: 18434566
[TBL] [Abstract][Full Text] [Related]
69. Inhibition of cyclooxygenase-2 attenuates urinary prostanoid excretion without affecting renal renin expression.
Kammerl MC; Nüsing RM; Seyberth HW; Riegger GA; Kurtz A; Krämer BK
Pflugers Arch; 2001 Sep; 442(6):842-7. PubMed ID: 11680616
[TBL] [Abstract][Full Text] [Related]
70. L-arginine reverses p47phox and gp91phox expression induced by high salt in Dahl rats.
Fujii S; Zhang L; Igarashi J; Kosaka H
Hypertension; 2003 Nov; 42(5):1014-20. PubMed ID: 14504257
[TBL] [Abstract][Full Text] [Related]
71. Role of neuronal nitric oxide synthase in Dahl salt-sensitive hypertension.
Tan DY; Meng S; Manning RD
Hypertension; 1999 Jan; 33(1 Pt 2):456-61. PubMed ID: 9931147
[TBL] [Abstract][Full Text] [Related]
72. Tempol attenuates the development of hypertensive renal injury in Dahl salt-sensitive rats.
Hisaki R; Fujita H; Saito F; Kushiro T
Am J Hypertens; 2005 May; 18(5 Pt 1):707-13. PubMed ID: 15882555
[TBL] [Abstract][Full Text] [Related]
73. Eplerenone shows renoprotective effect by reducing LOX-1-mediated adhesion molecule, PKCepsilon-MAPK-p90RSK, and Rho-kinase pathway.
Kobayashi N; Hara K; Tojo A; Onozato ML; Honda T; Yoshida K; Mita S; Nakano S; Tsubokou Y; Matsuoka H
Hypertension; 2005 Apr; 45(4):538-44. PubMed ID: 15710785
[TBL] [Abstract][Full Text] [Related]
74. A retrospective review of the effect of COX-2 inhibitors on blood pressure change.
Cho J; Cooke CE; Proveaux W
Am J Ther; 2003; 10(5):311-7. PubMed ID: 12975714
[TBL] [Abstract][Full Text] [Related]
75. Renal functional, not morphological, abnormalities account for salt sensitivity in Dahl rats.
Manger WM; Simchon S; Stokes MB; Reidy JJ; Kumar AR; Baer L; Gallo G; Haddy FJ
J Hypertens; 2009 Mar; 27(3):587-98. PubMed ID: 19330919
[TBL] [Abstract][Full Text] [Related]
76. Salt-induced hypertension in Dahl salt-sensitive rats. Hemodynamics and renal responses.
Simchon S; Manger WM; Carlin RD; Peeters LL; Rodriguez J; Batista D; Brown T; Merchant NB; Jan KM; Chien S
Hypertension; 1989 Jun; 13(6 Pt 1):612-21. PubMed ID: 2525523
[TBL] [Abstract][Full Text] [Related]
77. Dopamine D(3) receptors and salt-dependent hypertension.
Luippold G; Zimmermann C; Mai M; Kloor D; Starck D; Gross G; Mühlbauer B
J Am Soc Nephrol; 2001 Nov; 12(11):2272-2279. PubMed ID: 11675403
[TBL] [Abstract][Full Text] [Related]
78. Glucose metabolism and insulin receptor binding and mRNA levels in tissues of Dahl hypertensive rats.
Sechi LA; Griffin CA; Zingaro L; Catena C; De Carli S; Schambelan M; Bartoli E
Am J Hypertens; 1997 Nov; 10(11):1223-30. PubMed ID: 9397240
[TBL] [Abstract][Full Text] [Related]
79. Comparison of changes in blood pressure measurements and antihypertensive therapy in older, hypertensive, ambulatory care patients prescribed celecoxib or rofecoxib.
Nietert PJ; Ornstein SM; Dickerson LM; Rothenberg RJ
Pharmacotherapy; 2003 Nov; 23(11):1416-23. PubMed ID: 14620388
[TBL] [Abstract][Full Text] [Related]
80. Relationship between COX-2 specific inhibitors and hypertension.
Solomon DH; Schneeweiss S; Levin R; Avorn J
Hypertension; 2004 Aug; 44(2):140-5. PubMed ID: 15226279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
